Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

GLP-1 medications have become a popular tool for weight loss and metabolic health, but with their rise in popularity, ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Register today to learn how to build an effective, sustainable GLP-1 strategy that benefits everyone on your health plan.

A large population-based cohort study reports that using GLP-1 RAs significantly reduces the risk for cardiovascular events ...

CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

No significant difference seen in odds of postoperative pneumonia between adult GLP-1 receptor agonist users and nonusers.